Evidence map›Paper›PMID 40261141›Full record

ArticleAngewandte Chemie (International ed. in English)2025

Streamlining SuFEx Inhibitor Development: A Unified Approach Using Photolabile and Orthogonal Sulfinate Protecting Groups.

Twinkle I Patel, Makayla L Williams, Yumeng Chi, Ramkrishna Laha, Matthew J Moschitto

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Twinkle I PatelDepartment of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, 163 Frelinghuysen Road, Piscataway, New Jersey, USA.
Makayla L WilliamsDepartment of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, 163 Frelinghuysen Road, Piscataway, New Jersey, USA.
Yumeng ChiDepartment of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, 163 Frelinghuysen Road, Piscataway, New Jersey, USA.
Ramkrishna LahaDepartment of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, 163 Frelinghuysen Road, Piscataway, New Jersey, USA.
Matthew J MoschittoDepartment of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, 163 Frelinghuysen Road, Piscataway, New Jersey, USA.ORCID https://orcid.org/0000-0002-6758-7892

Funding

New Jersey Health Foundation PC203-24
6 · The paper itself

Abstract

Sulfonyl fluorides (SFs) have gained significant importance due to their classification as a click reaction and therefore have seen increased use in drug discovery and biochemistry. Their use, however, is complicated by the methods by which they are synthesized and their general synthetic instability. This results in SFs being introduced late in a synthetic route with minimal structural diversity. Masking the reactivity of a sulfonyl fluoride by protecting the parent sulfinate is one method to ameliorate these issues. Current sulfinate protecting groups (SPGs), however, possess limited stability. This study outlines the discovery and selection of SPGs based on their overall stability, ease of synthesis, and simple deprotection conditions. This includes the discovery of two novel, photolabile SPGs, para-methoxybenzyl Rongalite and ortho-nitrobenzyl Rongalite that can be directly converted to the sulfonyl fluoride using light and selectfluor. Along with known SPG, 2-trimethylsilylethyl sulfone (SES), all three SPGs were found to possess broad stability when exposed to numerous common synthetic conditions and are easily coupled to aryl halides from their sulfinate salt precursor. Their utility is then demonstrated in the synthesis of SPG containing building blocks that are incorporated into several bioactive small molecules.

Indexed as

Drug discoveryOrganosulfur chemistryPhotochemistrySulfonyl fluorides

Identifiers

PMID40261141
PMCPMC12207385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.